Biological age may matter more than calendar age in determining disease risk — and protein-based clocks could finally give clinicians a scalable way to measure it. A large European study now demonstrates that plasma proteomic signatures can predict a striking breadth of chronic disease outcomes across nearly three decades of follow-up, placing these tools on competitive footing with the lifestyle questionnaires that have anchored preventive medicine for generations.
Drawing on 17,473 participants from the European Prospective Investigation into Cancer and Nutrition (EPIC), with replication in the Whitehall II cohort, researchers used SomaScan-based plasma proteomics to construct both global and organ-specific biological age clocks. A composite metric — the global age gap, an acceleration score integrating multiple proteomic clocks — was significantly associated with smoking, alcohol consumption, and physical inactivity, and predicted elevated risk across 24 incident conditions including cardiovascular disease, dementia, and cancers of the liver, lung, upper aero-digestive tract, and kidney over up to 28 years. Critically, organ-specific age gaps showed particularly strong associations with cancers of the matching organ — lung, kidney, and stomach — suggesting these clocks capture tissue-level aging trajectories rather than simply reflecting systemic inflammation or generic frailty.
This work sits at the convergence of two maturing fields: multi-organ proteomic aging research pioneered largely through UK Biobank analyses, and long-horizon prospective epidemiology. What distinguishes this contribution is the organ-specificity dimension and the direct comparison of proteomic clock predictive performance against classical lifestyle risk scoring — a benchmark rarely attempted. The finding that the two approaches perform comparably is editorially significant: it positions proteomics not as a replacement for lifestyle assessment but as a potentially independent or complementary risk layer. Key limitations include the observational design, the predominantly European ancestry sample limiting generalizability, and the substantial cost and infrastructure still required for SomaScan assays in clinical settings. Nevertheless, this is among the most comprehensive validations of proteomic aging clocks to date — a confirmatory and potentially practice-shaping finding rather than merely incremental.
